| Literature DB >> 25317708 |
Jairo Lizarazo1, Patricia Escandón2, Clara Inés Agudelo2, Elizabeth Castañeda2.
Abstract
Cryptococcosis is reported in adults and is often acquired immune deficiency syndrome (AIDS)-associated; however, its frequency in children is low. Based on the National Survey on Cryptococcosis conducted in Colombia, an epidemiological and clinical analysis was performed on cases of the disease observed in children less than 16 years old between 1993-2010. We found 41 affected children (2.6% prevalence) from the 1,578 surveys received. The country mean annual incidence rate was 0.017 cases/100,000 children under 16 years, while in Norte de Santander the incidence rate was 0.122 cases/100,000 (p < 0.0001). The average age of infected children was 8.4 and 58.5% were male. In 46.3% of cases, a risk factor was not identified, while 24.4% had AIDS. The most frequent clinical manifestations were headache (78.1%), fever (68.8%), nausea and vomiting (65.6%), confusion (50%) and meningeal signs (37.5%). Meningitis was the most frequent clinical presentation (87.8%). Amphotericin B was given to 93.5% of patients as an initial treatment. Positive microbiological identification was accomplished by India ink (94.7%), latex in cerebrospinal fluid (100%) and culture (89.5%). Out of 34 isolates studied, Cryptococcus neoformans var. grubii (VNI 85.3%, VNII 8.8%) was isolated in 94.1% of cases and Cryptococcus gattii (VGII) was isolated in 5.9% of cases. These data are complemented by a literature review, which overall suggests that cryptococcosis in children is an unusual event worldwide.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25317708 PMCID: PMC4238773 DOI: 10.1590/0074-0276130537
Source DB: PubMed Journal: Mem Inst Oswaldo Cruz ISSN: 0074-0276 Impact factor: 2.743
Fig. 1: mean annual incidence of cryptococcosis in children < 16 years.
Fig. 2: cryptococcosis in Colombian children 1993-2010.
Clinical manifestations of cryptococcosis in children
| Clinical findings | n (%) |
|---|---|
| Headache | 25 (78.1) |
| Fever | 22 (68.8) |
| Nausea and vomiting | 21 (65.6) |
| Confusion | 16 (50) |
| Meningeal signs | 12 (37.5) |
| Visual alterations | 9 (28.1) |
| Seizures | 9 (28.1) |
| Cough | 6 (18.8) |
| Neurological signs | 6 (18.8) |
| Hydrocephalus | 6 (18.8) |
| Loss weight | 2 (6.2) |
n = 32.
Pharmacological treatment of cryptococcosis in Colombian children
| Treatment | n/total (%) |
|---|---|
| Patients with treatment | 31/41 (75.6) |
| Type of antifungal used | |
| AmB | 29/31 (93.5) |
| 5FC | 4/31 (12.9) |
| FCZ | 8/31 (25.8) |
| ITZ | 1/31 (3.2) |
| Caspofungin | 1/31 (3.2) |
| Therapeutic regimens used | |
| AmB only | 19/31 (61.3) |
| AmB + FCZ | 5/31 (16.1) |
| AmB + 5FC | 2/31 (6.4) |
| AmB + 5FC + FCZ | 1/31 (3.2) |
| AmB + ITZ | 1/31 (3.2) |
| AmB+ caspofungin | 1/31 (3.2) |
| 5FC + FCZ | 1/31 (3.2) |
| FCZ only | 1/31 (3.2) |
| Patients without treatment | 2/41 (4.9) |
| Patients without treatment information | 8/41 (19.5) |
AmB: amphotericin B; FCZ: fluconazole; ITZ: itraconazole; 5FC: 5-fluorocytosin.
Results of the laboratory examinations
| Type of examination | n/total (%) |
|---|---|
| Positive direct examination | 36/38 (94.7) |
| Capsular antigen detection | 14/14 (100) |
| Serum reactive | 4/4 (100) |
| CSF reactive | 10/10 (100) |
| Positive culture | 34/38 (89.5) |
| Serotype A | 32/34 (94.1) |
| Serotype B | 2/34 (5.9) |
| Molecular type | |
| VNI | 29 (85.3) |
| VNII | 3 (8.8) |
| VGII | 2 (5.9) |
| Mating type | |
| a | 1 (2.9) |
| alpha | 33 (97.1) |
| Isolates recovered from | |
| CSF | 27 (79.5) |
| CSF and blood | 3 (8.9) |
| Blood | 1 (2.9) |
| Skin | 1 (2.9) |
| CSF, BAL and skin | 1 (2.9) |
| Blood and BAL | 1 (2.9) |
BAL: bronchoalveolar lavage; CSF: cerebrospinal fluid.
Age, sex, prevalence and incidence of cryptococcosis in children in diverse countries around the world
| Region | Age (years)/ findings (%) | Reference |
|---|---|---|
| Colombia | 8.4 | This paper |
| Brazil | 7.6 and 7.8 (most HIV-) |
|
| 8.8 (all HIV-) |
| |
| Cuba | 5.8 (85.7 immunocompetent) |
|
| China | 7.25 (HIV-) |
|
| 10.9 (children up to 17 years) |
| |
| South Africa | 7 (91 HIV +) |
|
| Taiwan | 13.7 (all HIV- up to 17 years) |
|
| Thailand | 7 (all HIV+) |
|
| United States of America | 8 (all HIV+) |
|
| 9.8 (all HIV+) |
| |
| 11.5 (all HIV+) |
| |
| 11.98 (79.4 immunocompromised, up to 18 years) |
| |
|
| ||
| Region | Sex male (%) | Reference |
|
| ||
| Colombia | 58.5 | This paper |
| Brazil | 52.8 |
|
| Northern Brazil | 54.5 |
|
| Cuba | 42.9 |
|
| China | 60.87 |
|
| South Africa | 54.9 |
|
| 57 |
| |
| Taiwan | 22.2 |
|
| Thailand | 57.9 |
|
| United State of America | 60.3 |
|
|
| ||
| Region | Prevalence (%) | Reference |
|
| ||
| Colombia | 2.6 | This paper |
| Norte de Santander | 29.6 |
|
| Northern/northeastern Brazil | ||
| State of Bahia | 32 |
|
| State of Pará | 24 |
|
| State of Piauí | 9.5 |
|
| Africa | ||
| Botswana Ghana South Africa | 2.4 |
|
| 6.9 |
| |
| 2 |
| |
|
| ||
| Region | Prevalence (%) | Reference |
|
| ||
| Thailand | 3 |
|
| United States of America | 0.85 |
|
| 1.4 |
| |
| 3.3 |
| |
| French Guiana | 4.6 |
|
| Uruguay | 1.3 |
|
| Venezuela | 0.91 |
|
|
| ||
| Region | Incidence (cases x 100,000) | Reference |
|
| ||
| Colombia | 0.016 | This paper |
| Norte de Santander | 0.113 | This paper |
| China | 0.43 |
|
| South Africa | 1 47 (HIV+) |
|
| Gauteng | 38 (HIV+) |
|
| United States of America | 100 (HIV+) |
|